Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track VTVT with free AI briefings, catalyst countdowns, and dilution alerts.

VTVT · vTv Therapeutics Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$77.2M Cash on Hand
21.4mo Cash Runway
Follow VTVT by email Get an email when VTVT reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about VTVT, unsubscribe in one click. Privacy

📣 What VTVT Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Azeliragon Alzheimer's Disease Phase 3 · NCT02080364 Terminated
Cadisegliatin Diabetes Mellitus, Type 1 Phase 3 · NCT06334133 Active not recruiting
GK1-399 (formerly TTP399) Type 2 Diabetes Mellitus Phase 1/2 · NCT01474083 Completed
TTP054 Type 2 Diabetes Mellitus Phase 2 · NCT01665352 Completed
TTP273 Type 2 Diabetes Mellitus Phase 2 · NCT02653599 Completed
TTP399 Diabetes Mellitus, Type 1 Phase 1/2 · NCT03335371 Completed
TTP435 Obesity Phase 2 · NCT00779519 Completed
TTP889 Coagulation Phase 2 · NCT00909298 Terminated
TTP4000 Alzheimer's Disease Phase 1 · NCT01548430 Completed
Aurora Kinase Inhibitor TTP607 Advanced Cancers Phase 1 · NCT00939172 Withdrawn

Also used in these trials (approved or third-party drugs, not VTVT's own candidates): Sitagliptin.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

VTVT holds $77.2M in cash and short-term investments (as of Sep 30, 2026) and burns about $10.8M/quarter from operations, an estimated runway of 21.4 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 33 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when VTVT files for a raise →

Get the full VTVT picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for VTVT and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.